Metro Health Physician is First in United States to Use New Medical Device to Treat PAD
Posted: March 11, 2014
Metro Health cardiovascular specialist Dr. Jihad Mustapha is the first physician in the world to use a new medical device to treat peripheral arterial disease.
The nationally recognized physician dedicated to amputation prevention successfully debuted the new Diamondback 360® Peripheral Orbital Atherectomy System, or OAS, in a procedure yesterday at Metro Health. Developed by Minnesota-based Cardiovascular Systems, Inc., the new device allows physicians to gain access through the foot or ankle to clear blocked blood vessels below the knee due to its small profile and short length.
Mustapha successfully used the new device to clear a blockage in the limb of a Metro Health patient, who is a resident of Zeeland and a Vietnam War veteran. He is resting comfortably in his home and available for media interviews.
This is the third new medical device to debut at Metro Health to treat PAD. Over the past two years, Mustapha and other cardiovascular physicians have been selected to be the first in the United States – and on at least one occasion, the world – to use breakthrough technology.
The Diamondback 360 Peripheral OAS uses a patented combination of differential sanding and centrifugal force to reduce arterial plaque, including calcium, which can cause complications when treating PAD. PAD is a common circulatory problem in which narrowed arteries block the blood flow to arms and legs, causing numbness, leg pain, tissue damage and leading to amputation.
The hospital has developed a nationally recognized specialty in the treatment of PAD and amputation prevention, last year treating scores of patients from around Michigan, across the country and throughout the world. Led by Mustapha, Metro Heart & Vascular physicians utilize leading-edge technology, such as the new Diamondback device, to clear blockages and restore circulation in even the most challenging of cases.
“Many of the patients we treat have an advanced form of PAD known as critical limb ischemia, or CLI,” Mustapha explained. “These patients often have complex, calcified lesions in their lower leg which are challenging to access and treat using the traditional femoral artery access site.
“CSI’s new orbital atherectomy system now allows us more options to treat those lesions by providing a low-profile system that is fully compatible with alternative access sites in the foot or ankle. Having a variety of treatment options allows us to treat more patients who may otherwise be facing amputation.”
As many as 12 million Americans, most over the age of 65, suffer from PAD, which is caused by the accumulation of plaque in peripheral arteries reducing blood flow. Left untreated, PAD can lead to severe pain, immobility, non-healing wounds and eventually amputation.
Calcium is present in about 65 percent of the 2.5 million people diagnosed annually with PAD and leads to poor outcomes and higher treatment costs when traditional balloon and stent therapies are used.
Patients at high risk include those who are obese or have diabetes, heart disease or other circulatory issues. Smokers are also at a higher risk, as are African Americans and Native Americans.
For more information on Metro Heart & Vascular, visit http://metrohealth.net/medical-services/heart-vascular-services/.
For more information on the Diamondback 360 Peripheral OAS, visit Cardiovascular Systems, Inc